Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Diet Begins Deliberations on Amendment of PMD Act, Bill to Repeal Off-Year Scheme
Japan’s Diet kicked off debates on a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at a Lower House health committee session on April 4. An opposition-sponsored bill designed to virtually scrap “off-year” drug price revisions also entered…
To read the full story
Related Article
- Japan’s Parliament Enacts Bill to Amend PMD Act
May 15, 2025
- Bill to Amend PMD Act Now in Upper House Deliberations
April 23, 2025
- Lower House Passes Bill to Amend PMD Act
April 21, 2025
- Lower House Health Committee OKs Bill to Amend PMD Act, Adopts Supplementary Resolution
April 17, 2025
- PMD Act Bill Set for Lower House Committee Vote on April 16
April 16, 2025
- Nippon Ishin Co-Leader Shows Understanding of Off-Year Price Revisions
April 11, 2025
- Bill to Nix Off-Year Scheme Politicized, Could Clear Lower House with Ishin Support
April 10, 2025
- PMD Act Amendment to Enter Diet Debate; Parallel Deliberations Planned for Bill to Scrap Off-Year Revisions
April 3, 2025
- Japan Cabinet Approves Bill to Amend PMD Act
February 13, 2025
- CDP OKs Bill to Scrap Off-Year Revisions, Aims for Diet Submission Soon
December 13, 2024
REGULATORY
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…